Skip to content
Giapreza(angiotensin ii)
Giapreza (angiotensin ii) is a protein pharmaceutical. Angiotensin ii was first approved as Giapreza on 2017-12-21. It is used to treat hypotension in the USA. It has been approved in Europe to treat hypotension and shock. It is known to target type-2 angiotensin II receptor, proto-oncogene Mas, potassium channel subfamily K member 3, and type-1 angiotensin II receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Giapreza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Angiotensin ii acetate
Tradename
Company
Number
Date
Products
GIAPREZALa Jolla Pharmaceutical CompanyN-209360 RX2017-12-21
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
giaprezaNew Drug Application2020-06-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypotensionEFO_0005251D007022I95
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Angiotensin Ii Acetate, Giapreza, La Jolla Pharma
112196622037-01-06U-3262
92207452034-12-18U-2217, U-2218
100289952034-12-18U-2338
104931242034-12-18U-2679
110969832034-12-18U-3211, U-3212
115595592034-12-18U-3514
95728562031-07-18U-2221
98678632029-12-16U-2231
103354512029-12-16U-2581
105002472029-12-16U-2680, U-2681
105489432029-12-16U-2739, U-2740
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01C: Cardiac stimulants excl. cardiac glycosides
— C01CX: Other cardiac stimulants in atc
— C01CX09: Angiotensin ii
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
— C09DX: Angiotensin ii receptor blockers (arbs), other combinations
HCPCS
No data
Clinical
Clinical Trials
47 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I103235214
Septic shockD012772A48.31212—6
Acute kidney injuryD058186HP_0001919N17—2—2—4
Heart failureD006333EFO_0003144I501—21—4
Liver cirrhosisD008103EFO_0001422K74.0—1—1—2
End stage liver diseaseD058625EFO_1001311K72.1———1—1
HypotensionD007022EFO_0005251I95———1—1
Surgical shockD012773EFO_0007686———1—1
ShockD012769R57.1———1—1
DyslipidemiasD050171HP_0003119———1—1
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SepsisD018805A41.9—21—14
Covid-19D000086382U07.1——1—23
Cognitive dysfunctionD060825G31.84—21——2
Myocardial infarctionD009203EFO_0000612I21——2——2
AtherosclerosisD050197EFO_0003914I25.1——2——2
VasoplegiaD056987—12——2
Cardiovascular diseasesD002318EFO_0000319I98——1——1
Alzheimer diseaseD000544EFO_0000249F03—11——1
Membranous glomerulonephritisD015433EFO_0004254N03.2——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatorenal syndromeD006530K76.711———2
DementiaD003704F03—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Insulin resistanceD007333EFO_00026141———12
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.91————1
Pulmonary arterial hypertensionD0000810291————1
Postural orthostatic tachycardia syndromeD054972G90.A1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Systolic heart failureD054143EFO_1001207I50.20————11
FrailtyD000073496R53.1————11
Respiratory distress syndromeD012128EFO_1000637J80————11
Renal insufficiencyD051437HP_0000083N19————11
Diabetes mellitusD003920EFO_0000400E08-E13————11
Hiv infectionsD015658EFO_0000764B20————11
Type 1 diabetes mellitusD003922EFO_0001359E10————11
HypoglycemiaD007003HP_0001943E16.2————11
Renin-angiotensin systemD012084————11
MicrocirculationD008833————11
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameANGIOTENSIN II
INNangiotensin ii
Description
Ile(5)-angiotensin II is an angiotensin II that acts on the central nervous system (PDB entry: 1N9V). It has a role as a human metabolite. It is a tautomer of an Ile(5)-angiotensin II dizwitterion.
Classification
Protein
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
Identifiers
PDB—
CAS-ID11128-99-7
RxCUI—
ChEMBL IDCHEMBL408403
ChEBI ID2719
PubChem CID172198
DrugBank—
UNII IDM089EFU921 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
AGTR2
AGTR2
MAS1
MAS1
KCNK3
KCNK3
AGTR1
AGTR1
Organism
Homo sapiens
Gene name
AGTR2
Gene synonyms
NCBI Gene ID
186
Protein name
type-2 angiotensin II receptor
Protein synonyms
Angiotensin II type-2 receptor, AT2 receptor
Uniprot ID
Q6FGY7
Mouse ortholog
Agtr2 (11609)
type-2 angiotensin II receptor (P35374)
Variants
Clinical Variant
No data
Financial
Giapreza - Innoviva, Inc.
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 259,404 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
264 adverse events reported
View more details